Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Observational Clinical Study of Autologous Hematopoietic Stem Cell Transplantation and Chemotherapy as First-Line Consolidation Therapy After Obtaining a Complete Therapeutic Response in T-Cell Lymphoma

ID
Name
2023PHB202-001
Description
To compare the effectiveness of autologous hematopoietic stem cell transplantation and chemotherapy as first-line consolidation therapy after obtaining a complete therapeutic response in T-cell lymphoma through a multicenter retrospective real-world study in China.
Trial arms
Trial start
2014-01-01
Estimated PCD
2022-01-01
Trial end
2023-07-01
Status
Completed
Treatment
consolidation with ASCT
high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
Arms:
Consoliation with ASCT
Other names:
consoliation therapy
Size
347
Primary endpoint
overall survival
through study completion, an average of 2 year
Eligibility criteria
Inclusion Criteria: * Pathological diagnosis of T-cell lymphoma, including, but not limited to, Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), Angioimmunoblastic T-cell lymphoma (AITL) , ALK-negative anaplastic large cell lymphoma (ALCL, ALK-negative), Enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma (HSTCL), and extranodal NK/T-cell lymphoma (ENKTL ) * 18-75 years old; * Achievement of a complete response (CR) post-chemotherapy; * Obtaining a complete response (CR) after chemotherapy;-Consistent follow-up visits post-treatment, with comprehensive follow-up data available; Exclusion Criteria: * Initially diagnosed with ALK-positive Anaplastic Large Cell Lymphoma (ALCL, ALK- - -CR was not achieved after treatment; * Lack of complete follow-up information or lack of consent for follow-up and data collection * T-cell lymphoma secondary to other malignancies
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 347, 'type': 'ACTUAL'}}
Updated at
2023-11-29

1 organization

1 product

1 indication

Organization
Huazhong University of Science and Technology
Product
Consolidation with ASCT
Indication
T-cell lymphoma